Carolinas Wealth Consulting’s Crescent Biopharma CBIO Stock Holding History

Carolinas Wealth Consulting’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-4	Closed	-$687	–	1054
2023 Q2	$687	Hold	4	–	–	﹤0.01%	955
2023 Q1	$498	Hold	4	–	–	﹤0.01%	990
2022 Q4	$1.2K	Hold	4	–	–	﹤0.01%	875
2022 Q3	$0	Hold	4	–	–	﹤0.01%	899
2022 Q2	$0	Hold	4	–	–	﹤0.01%	911
2022 Q1	$0	Hold	4	–	–	﹤0.01%	946
2021 Q4	$1K	Hold	4	–	–	﹤0.01%	883
2021 Q3	$1K	Hold	4	–	–	﹤0.01%	861
2021 Q2	$1K	Hold	4	–	–	﹤0.01%	871
2021 Q1	$1K	Hold	4	–	–	﹤0.01%	871
2020 Q4	$1K	Hold	4	–	–	﹤0.01%	797
2020 Q3	$1K	Hold	4	–	–	﹤0.01%	827
2020 Q2	$1K	Buy	+4	New	+$1.13K	﹤0.01%	568

Other funds holding CBIO

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Carolinas Wealth Consulting's CBIO Position: Q3 2023 in Review

Carolinas Wealth Consulting sold out of Crescent Biopharma (CBIO) in Q3 2023, closing a stake of 4 shares — an estimated $687 sold.

Carolinas Wealth Consulting first reported a position in CBIO in Q2 2020 and held it in 13 quarters. The position peaked at $1.2K in Q4 2022. 49 funds tracked by Wall St. Rank hold CBIO as of Q3 2023.

Carolinas Wealth Consulting reported no remaining Crescent Biopharma position as of Q3 2023 after selling out during the quarter.
Carolinas Wealth Consulting sold 4 Crescent Biopharma shares in Q3 2023, an estimated $687.
Carolinas Wealth Consulting first reported a position in Crescent Biopharma in Q2 2020 and held it in 13 quarters.
Carolinas Wealth Consulting's Crescent Biopharma position peaked at $1.2K in Q4 2022.
49 funds tracked by Wall St. Rank held Crescent Biopharma as of Q3 2023.

Based on Carolinas Wealth Consulting's 13F filing for Q3 2023, filed 14 Nov 2023.